Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Small Cell
Proto-Oncogene Proteins c-bcl-2
The combination of G3139, carboplatin, and etoposide is well tolerated and results in an encouraging response rate and time to progression in patients with extensive stage SCLC.
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency